# Ignace Vergote

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ignace-vergote/

## Facts

| Field | Value |
| --- | --- |
| Citations | 92,159 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 136 |
| i10-index | 785 |
| Last Known Institution | Gynecologic Oncology Group |
| OpenAlex ID | https://openalex.org/A5058535647 |
| ORCID iD | 0000-0002-7589-8981 |
| Works | 1,876 |

## Researcher papers

Showing 12 of 31.

- [Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer](https://scholariq.org/papers/neoadjuvant-chemotherapy-or-primary-surgery-in-stage-iiic-or-iv-ovarian-cancer/)
- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [Epithelial ovarian cancer](https://scholariq.org/papers/epithelial-ovarian-cancer/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial](https://scholariq.org/papers/bevacizumab-combined-with-chemotherapy-for-platinum-resistant-recurrent-ovarian/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms](https://scholariq.org/papers/a-randomized-trial-of-lymphadenectomy-in-patients-with-advanced-ovarian/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

## Researcher university

- [Gynecologic Oncology Group](https://scholariq.org/institutions/gynecologic-oncology-group/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.